Harmony Biosciences(HRMY) Prnewswire·2025-03-03 18:15Core Viewpoint - Harmony Biosciences Holdings, Inc. is under investigation for potential securities fraud and unlawful business practices following a negative FDA response regarding its drug pitolisant [1][2]. Group 1: Company Overview - Harmony Biosciences Holdings, Inc. trades on NASDAQ under the ticker HRMY [1]. - The company recently received a Refusal to File (RTF) letter from the FDA concerning pitolisant, which is intended for treating excessive daytime sleepiness in adult patients with idiopathic hypersomnia [2]. Group 2: Financial Impact - Following the FDA's announcement, Harmony's stock price dropped by $3.77 per share, representing a decline of 9.64%, closing at $35.32 per share on February 19, 2025 [2]. Group 3: Legal Context - Pomerantz LLP is leading the investigation into Harmony, focusing on whether the company and its officers engaged in securities fraud or other unlawful practices [1]. - Pomerantz LLP has a long history in corporate and securities class litigation, having recovered significant damages for victims of securities fraud [3].